• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Universal Display Corporation Acquires Merck KGaA, Darmstadt, Germany’s Phosphorescent OLED Emitter Intellectual Property Assets and Enters into Multi-Year Collaboration Agreement

Share:

May 9, 2023

Universal Display Corporation (UDC) has acquired the phosphorescent OLED emitter intellectual property (IP) assets of Merck KGaA. The portfolio, which has an average lifetime of 10 years, includes over 550 issued and pending patents worldwide in 172 patent families, representing more than 15 years of research and development. UDC has also entered into a new multi-year collaboration agreement with Merck KGaA that pertains to UDC’s leading-edge green and yellow phosphorescent emitters and Merck’s transport and host materials. The strategic acquisition enhances UDC’s position in the OLED ecosystem and its extensive research and intellectual property portfolios.

Universal Display Corporation (Nasdaq: OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, announced today that through its wholly-owned subsidiary UDC Ireland Limited, UDC has acquired the Phosphorescent OLED Emitter Intellectual Property (IP) assets of Merck KGaA, Darmstadt, Germany, a leading science and technology company. Representing more than 15 years of research and development, this portfolio has an average lifetime of 10 years and includes over 550 issued and pending patents around the world in 172 patent families. In addition, Universal Display Corporation and Merck KGaA, Darmstadt, Germany, entered into a new multi-year collaboration agreement that pertains to UDC’s leading-edge green and yellow phosphorescent emitters and Merck KGaA, Darmstadt, Germany’s state-of-the-art transport and host materials to create advanced PHOLED stacks.
“We are pleased to complement and boost our vast global IP framework with Merck KGaA, Darmstadt, Germany’s phosphorescent emitter patents and announce the extension and expansion of our OLED materials partnership,” said Steven V. Abramson, President and Chief Executive Officer of Universal Display. “This strategic acquisition enhances our robust position in the OLED ecosystem. As the pioneer and leader in phosphorescent OLED technologies and materials, we are well situated to leverage Merck KGaA, Darmstadt, Germany’s discoveries into our extensive research and intellectual property portfolios.”

“This portfolio represents the culmination of years of research by distinguished scientists and we are pleased that UDC will incorporate our inventions into their worldwide patent portfolio and competencies,” said Dr. Gottfried Wastlbauer, Head of Global Marketing of Display Solutions at the Electronics business of Merck KGaA, Darmstadt, Germany. “We believe that our triplet emitter IP and know-how seamlessly fits into UDC’s comprehensive intellectual property library and that these assets will be well maximized in their research and development programs. The new partnership with UDC is a strategic move towards accelerating the growth of our OLED business. As a leading OLED material company, having access to UDC’s leading-edge emitters will benefit our development of transport materials and most importantly boost our capabilities to develop new host materials.”

Source: BioSpace

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Australian Medtech Startup Nutromics Bags $4M in Pre-Market Funding for Continuous Molecular Monitoring DeviceAustralian Medtech Startup Nutromics Bags $4M in Pre-Market Funding for Continuous Molecular Monitoring Device
  • Owkin Lands $25M for AI-powered Research Platform, Braid Health Scores $9M for Teleradiology and More Digital Health FundingOwkin Lands $25M for AI-powered Research Platform, Braid Health Scores $9M for Teleradiology and More Digital Health Funding
  • Cresco Labs to Acquire Origin House in Largest-Ever Public Company Acquisition in the U.S. Cannabis SectorCresco Labs to Acquire Origin House in Largest-Ever Public Company Acquisition in the U.S. Cannabis Sector
  • Ecolab Acquires Gallay Medical & ScientificEcolab Acquires Gallay Medical & Scientific
  • AireHealth’s Respiratory Health Assets to be Auctioned off in September.AireHealth’s Respiratory Health Assets to be Auctioned off in September.
  • 3 key ways blockchain could change radiology forever3 key ways blockchain could change radiology forever
  • Picking Up the Pace: Healthcare’s Evolution to Social MediaPicking Up the Pace: Healthcare’s Evolution to Social Media
  • As JPM 2019 wraps up, biopharma’s outlook is ‘cautiously optimistic,’ executives sayAs JPM 2019 wraps up, biopharma’s outlook is ‘cautiously optimistic,’ executives say

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications